Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
134 hedge funds and large institutions have $386M invested in Synergy Pharmaceuticals, Inc Common Stock in 2016 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 51 increasing their positions, 31 reducing their positions, and 21 closing their positions.
118% more capital invested
Capital invested by funds: $177M → $386M (+$209M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
70% more call options, than puts
Call options by funds: $4.64M | Put options by funds: $2.74M
65% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 31
29% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 21
5% more funds holding
Funds holding: 128 → 134 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
+$56.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.6M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$18.4M |
| 4 |
O
OrbiMed
New York
|
+$12.5M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$5.62M |
| 2 |
TS
Twin Securities
New York
|
-$4.66M |
| 3 |
AC
Armistice Capital
New York
|
-$2.95M |
| 4 |
Millennium Management
New York
|
-$2.64M |
| 5 |
FHAM
Folger Hill Asset Management
New York
|
-$2.21M |
SGYP Hedge Fund Activity: Q2 2016 in Review
134 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q2 2016, worth a combined $386M — up 118% from $177M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SGYP positions and 21 closed out — a net gain of 6 holders — while 51 added to existing stakes and 31 trimmed.
The largest buyer was Paulson & Co, adding an estimated $56.5M. The largest seller was Franklin Resources, exiting entirely with an estimated $5.62M sold.
- 134 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q2 2016, up from 128 in Q1 2016.
- Funds reported $386M of Synergy Pharmaceuticals, Inc Common Stock stock for Q2 2016, up 118% quarter-over-quarter.
- 27 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q2 2016 and 21 closed out, a net change of +6 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q2 2016 was Paulson & Co, an estimated $56.5M added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q2 2016 was Franklin Resources, an estimated $5.62M sold.
Based on aggregated 13F filings for Q2 2016.